<DOC>
	<DOCNO>NCT00990665</DOCNO>
	<brief_summary>The objective study assess safety efficacy Quartet™ lead Promote Q® device system patient population indicate cardiac resynchronization therapy .</brief_summary>
	<brief_title>Promote Q Cardiac Resynchronization Therapy Defibrillator ( CRT-D ) Quartet Left Ventricular Heart Lead Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<criteria>Approved indication per ACC/AHA/HRS guideline implantation CRTD system treatment heart failure lifethreatening ventricular tachyarrhythmia ( ) Receiving new implant undergoing upgrade exist ICD pacemaker implant prior LV lead placement . Ability provide inform consent study participation willing able comply prescribe followup test schedule evaluation Have recent CVA TIA within three month enrollment Have contraindication emergency thoracotomy Have hypersensitivity single 1.0mg dose dexamethasone sodium phosphate short term contact heparin Have classification Status 1 cardiac transplantation consideration transplantation next 3 month Have undergone cardiac transplantation within 40 day enrollment Have recent myocardial infarction , unstable angina cardiac revascularization ( PTCA , Stent CABG ) within 40 day enrollment Are currently participate clinical investigation include active treatment arm Are pregnant plan become pregnant duration study Have life expectancy le 6 month due condition Are less 18 year age Are unable comply follow schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>CRT</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>LV Leads</keyword>
</DOC>